HTHamidou Traore

Hamidou Traore

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hamidou Traore has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Addressing the Key Challenges of Decentralized Clinical Trials in Europe: Multistakeholder Perspective Delphi Study

    by Carlos Murciano-Gamborino, Lina Pérez-Breva, Amos J de Jong, Martin Boeckhout, Ghislaine Jose Madeleine Wilhelmien van Thiel, Kate Huntley, Hamidou Traore, Helga Gardarsdottir, Jaime Fons-Martinez

    Background: Decentralized clinical trials (DCTs) represent an emerging model in clinical research, accelerated by the restrictions imposed during the COVID-19 pandemic. By leveraging digital technologies and local health care resources, DCTs aim to increase accessibility and reduce participant burden compared to traditional site-based models, which often face recruitment failures and high attrition rates. While various regulatory initiatives in Europe, such as the Accelerating Clinical Trials in the European Union program and the European Medicines Regulatory Network recommendation paper (updated in October 2025), have sought to facilitate their implementation, the widespread adoption of DCTs remains limited due to significant operational, regulatory, and technological challenges, including platform fragmentation and gaps in digital literacy. Objective: This study aimed to identify and prioritize actionable solutions to the main challenges of DCT implementation in Europe from a multistakeholder perspective, gathering insights to address specific ethical, legal, and operational barriers. Methods: Building on a preceding strengths, weaknesses, opportunities, and threats analysis, a 2-round Delphi study was conducted, involving 26 experts in clinical trials, ethics, law, regulation, and patient engagement between March and May 2023. In the first round, 309 open-ended responses were collected via REDCap (Research Electronic Data Capture; Vanderbilt University) surveys and underwent systematic inductive content analysis using ATLAS.ti (ATLAS.ti Scientific Software Development GmbH) with independent double coding. This process resulted in 244 unique proposals that were categorized according to 6 key challenges. In the second round, 39 synthesized proposals were evaluated using a 4-point Likert scale. Consensus was defined as ≥80% agreement on the appropriateness of each proposal. Results: High levels of consensus were achieved, with 32 out of the 39 proposals reaching the threshold and 14 achieving 100% unanimity. Overall, 82% of the proposals were rated as “appropriate” or “very appropriate.” Key recommendations included providing support and training for health care professionals, enhancing investigational medicinal product and biological sample logistics through validated technologies, improving collaboration with local health care providers, fostering regulatory harmonization while respecting national specificities, strengthening capacity-building initiatives, and promoting accessible, user-friendly digital tools supported by hybrid trial models. Conversely, proposals such as peer-to-peer participant support and the centralization of ethics reviews at the European Union level failed to reach consensus. Conclusions: The study offers a prioritized compilation of expert-driven recommendations for overcoming current barriers to DCT implementation in Europe. The adoption of these recommendations could support the development of more inclusive, efficient, and sustainable decentralized research frameworks across diverse health care systems.

  • Open Access

    Regulatory Interactions and Learnings— RADIAL the Trials@Home Proof‐of‐Concept Trial on Decentralization

    by Helga Gardarsdottir, Hamidou Traore, Kate Huntley, Dinesh Mistry, Amos J. de Jong, Agnes Legathe, Tim de Smedt, Scott Askin, Megan Heath, Solange Corriol‐Rohou, et al.

    This paper is part of a series of six publications presenting lessons learned during the setup, regulatory submission, and conduct of the proof‐of‐concept Trials@Home RADIAL trial. The three‐arm RADIAL trial, comprising fully decentralized, hybrid, and conventional arms, is the first clinical study to evaluate the feasibility and acceptability of decentralized clinical trial elements across six European countries. In this paper, insights from multiple formal regulatory interactions related to the RADIAL trial, conducted between 2021 and 2022, are presented. These interactions included (i) a consultation with the European Medicines Agency’s Innovation Task Force, (ii) a national Scientific Advice procedure, and (iii) the clinical trial application submission under the EU Clinical Trials Regulation (Regulation EU 536/2014). Given the novelty of the decentralized approach and lack of guidelines, many constructive comments and questions were received that supported the finalization of the protocol and conduct of the trial. It is important to acknowledge that clinical trials often span multiple countries and regulatory jurisdictions, creating complexity due to variations in complementary national legal and regulatory requirements. We conclude that early and continuous regulatory engagement is essential for the successful implementation of innovative trial designs. Although progress has been made in supporting decentralized clinical trials, persistent challenges related to legislative heterogeneity remain. Harmonized regulatory guidance and greater transparency through the sharing of regulatory experiences will be key to facilitating the broader adoption of decentralized approaches and advancing clinical trials in Europe.